Rep. Thomas H. Kean, Jr. Sells Off Johnson & Johnson (NYSE:JNJ) Shares

Key Points

• Rep. Thomas H. Kean Jr. sold $1,001–$15,000 of Johnson & Johnson shares on August 27, according to a September 12 disclosure. He also sold Microsoft and Alphabet shares while buying MasTec during the same period.
• Johnson & Johnson reported stronger-than-expected quarterly results, with $2.90 in adjusted EPS and $25.31 billion in revenue, while maintaining a quarterly dividend of $1.34 per share.
• JNJ shares opened at $266.81, and analysts maintain a “Moderate Buy” consensus with an average price target of $274.13. Potential growth drivers include a possible $20 billion sale of DePuy Synthes and positive RYBREVANT lung-cancer trial results, while a failed depression-drug trial presents a pipeline setback.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on August 27th. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 8/27/2026.
• Purchased $1,001 - $15,000 in shares of MasTec NYSE: MTZ on 8/21/2026.
• Sold $1,001 - $15,000 in shares of Stryker NYSE: SYK on 7/22/2026.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 7/22/2026.
• Purchased $1,001 - $15,000 in shares of Toast NYSE: TOST on 7/8/2026.
• Purchased $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 7/8/2026.
• Purchased $1,001 - $15,000 in shares of ESAB NYSE: ESAB on 7/7/2026.
• Purchased $1,001 - $15,000 in shares of EQT NYSE: EQT on 7/7/2026.
• Sold $1,001 - $15,000 in shares of Analog Devices NASDAQ: ADI on 6/30/2026.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $266.81 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm's 50-day simple moving average is $263.18 and its 200 day simple moving average is $246.08. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07. The stock has a market cap of $642.99 billion, a price-to-earnings ratio of 30.92, a PEG ratio of 2.54 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is 62.11%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. Corporate insiders own 0.16% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J is reportedly in discussions with Apollo Global Management to sell its DePuy Synthes orthopedics business for approximately $20 billion. A transaction could unlock significant value, provide capital for debt reduction, buybacks or acquisitions, and sharpen the company’s focus on higher-growth businesses. However, DePuy Synthes generated $9.3 billion in sales last year, so investors will weigh proceeds against the loss of ongoing revenue. J&J in talks to sell DePuy Synthes to Apollo for $20 billion
• Positive Sentiment: Phase 3 PAPILLON results for RYBREVANT plus chemotherapy showed median overall survival of 34.3 months in patients with EGFR exon 20 insertion-positive non-small cell lung cancer. The durable benefit strengthens the commercial outlook for a key oncology product and supports J&J’s strategy of offsetting pressure from older medicines. RYBREVANT PAPILLON study results
• Positive Sentiment: Management is targeting double-digit growth despite anticipated biosimilar competition for STELARA, suggesting confidence in new product launches, oncology momentum and broader pharmaceutical diversification. Johnson & Johnson targets double-digit growth
• Neutral Sentiment: At the Morgan Stanley healthcare conference, J&J presented its business outlook and strategy; the available report provides no specific new guidance likely to materially change earnings expectations. Morgan Stanley healthcare conference transcript
• Negative Sentiment: Contineum Therapeutics said the mid-stage trial of JNJ-5120, or PIPE-307, failed to meet its primary objective in major depressive disorder. The failure removes or delays a potential pipeline opportunity, though the financial impact may be limited because the program is partnered. Contineum and J&J depression drug trial
• Negative Sentiment: J&J’s requirement that providers submit claims data to receive 340B discounts could generate pushback from hospitals and safety-net providers, increasing reputational, legal or policy risk around the company’s pricing practices. J&J 340B reporting requirement

Analyst Ratings Changes

A number of brokerages have recently commented on JNJ. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Bank of America lifted their price target on Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a research note on Friday, July 10th. UBS Group assumed coverage on Johnson & Johnson in a report on Wednesday, September 2nd. They issued a "buy" rating and a $320.00 price target for the company. Weiss Ratings upgraded Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research report on Friday, July 24th. Finally, Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $274.13.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Outlook Capital Management LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $28,000. Blueline Advisors LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $25,000. Matrix Trust Co grew its holdings in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after purchasing an additional 54 shares during the period. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Johnson & Johnson by 946.7% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock valued at $32,000 after purchasing an additional 142 shares during the period. Finally, Montgomery Financial Services LLC bought a new position in Johnson & Johnson in the 2nd quarter worth about $43,000. 69.55% of the stock is owned by institutional investors and hedge funds.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.